UroViu

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced a strategic collaboration with US firm UroViu Corporation, obtaining exclusive global rights to UroViu’s patented portable single-use cystoscope in the field of fluorescent imaging. Combining Technology for Non-Muscle Invasive Bladder Cancer (NMIBC) ResearchUnder the agreement, Asieris will utilize this patented…